Áttétes emlőrák: vizsgálatok itt: Kína
224 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07125950 - 2. fázisTaking peopleThe Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 184
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07203729 - 2. fázisTaking peopleSMP-656 for HER2-Positive Advanced Breast Cancer
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 60
- Run by
- Chengdu SciMount Pharmatech Co., Ltd.
See details and how to joinNCT07726342 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 180
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06439771 - 2. fázisTaking peopleA Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 87
- Run by
- Shenyang Sunshine Pharmaceutical Co., LTD.
See details and how to joinNCT07757230 - 2. fázisTaking peopleA Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 48
- Run by
- Henan Cancer Hospital
See details and how to joinNCT06598046 - 1/2. fázisTaking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Életkor
- 18 év and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844 - 2. fázisTaking peopleTrastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 224
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07100600 - 3. fázisNot yet taking people in KínaPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Beijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Quanzhou, Shaoyang, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - 2. fázisTaking peopleA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 210
- Run by
- Minghui Pharmaceutical (Hangzhou) Ltd
See details and how to joinNCT07130383 - 3. fázisTaking peopleA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- Where
- Changsha, Guangzhou
- Életkor
- 18 év to 75 év
- People
- 240
- Run by
- Shandong Suncadia Medicine Co., Ltd.
See details and how to joinNCT07024173 - 3. fázisTaking peopleA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Where
- Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00 - No phaseTaking peopleA Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer
- Where
- Guangdong
- Életkor
- 18 év to 75 év
- People
- 15
- Run by
- Jie Yuan,MD
See details and how to joinNCT07850869 - 2. fázisTaking peopleT-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 202
- Run by
- Fudan University
See details and how to joinNCT07152782 - 2. fázisTaking peopleT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 140
- Run by
- Fudan University
See details and how to joinNCT07150208 - 3. fázisTaking peopleA Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 366
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT04400695 - 2. fázisNot yet taking people in KínaA Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
- Where
- Fujian
- Életkor
- 18 év and over
- People
- 28
- Run by
- Fujian Medical University
See details and how to joinNCT07836257 - 2. fázisNot yet taking people in KínaProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 225
- Run by
- Fudan University
See details and how to joinNCT07825753 - No phaseTaking peopleTiming of ctDNA Testing in Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 400
- Run by
- Geneplus-Beijing Co. Ltd.
See details and how to joinNCT07681323 - 1. fázisTaking peopleBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Where
- Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06756932 - 2. fázisTaking peopleA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07678957 - 2. fázisTaking peoplePhase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07817082 - No phaseTaking peopleHER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 100
- Run by
- Fudan University
See details and how to joinNCT07586215 - 1. fázisTaking peopleA Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 39
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07753226 - 2. fázisTaking peopleDalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07810088